1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
27,36,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 50.12 | 32.75 | 17.10 |
| Total Income | 46.12 | 24.48 | 1.72 |
| Profit After Tax | 4.26 | 1.93 | -0.93 |
| EBITDA | 9.21 | 4.57 | -0.69 |
| NET Worth | 9.47 | 5.21 | 3.27 |
| Reserves and Surplus | 5.22 | 0.96 | -0.98 |
| Total Borrowing | 19.14 | 19.22 | 10.35 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹140.05 (+0.21%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹41.00 (+2.27%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹190.90 (+1.06%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹278.00 (+3.93%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹252.00 (+1.10%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹110.50 (-1.34%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹251.20 (+1.45%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹69.43 (-2.84%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹559.35 (-1.38%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,090.20 (+2.29%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,516.90 (+0.19%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹167.93 (+2.00%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.37 (+2.33%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment in full or in part, of certain of our outstanding borrowings | 9.00 |
| 2 | Funding capital expenditure towards purchase of new machinery | 6.08 |
| 3 | Funding to meet Working Capital requirements | 15.00 |
| 4 | General Corporate Purpose |
About Rednex Pharmaceuticals IPO
Incorporated in 2020, Rednex Pharmaceuticals is a pharmaceutical manufacturing company, producing a wide range of medicines used across various therapeutic areas such as antibacterial, antifungal, antimalarial, pain relief, antacid, antiallergy, and more. The company also manufactures medicines for other companies under loan license and contract manufacturing arrangements. Its manufacturing facility is located in Bavla, Ahmedabad, covering 9,212.63 sq. meters, and includes two separate manufacturing units: General Pharma Plant– Produces common formulations like tablets, capsules, syrups, creams, gels, ointments, and lotions. Beta Lactam Plant– Specially designed to manufacture antibiotics such as Cefixime, Amoxicillin, Cefuroxime, and Cephalexin, in tablets, capsules, and dry syrup forms. This unit operates independently to prevent contamination and meet international quality standards. The manufacturing facility is well equipped with modern automated machinery, in-house laboratories, and storage facilities for raw materials and finished goods. It also hold certifications such as FDCA License, WHO Certificate, ISO 9001:2015 (Quality Management), and ISO 14001:2015 (Environmental Ma
Contact Details
Rednex Pharmaceuticals Ltd. AddressSurvey No. 586 and 231,Near SKF Bearing, Bavla Bagodara N.H 8A,Kerala, Taluka: Bavla,Ahmedabad, Gujarat, 382220+91- 83201-31437info@rednexpharma.comVisit Website